Medisyn Technologies

	David Land Awarded "Best of Show" at Minnesota Venture Capital Conference Minneapolis, May 10, 2002 - Four start-up companies received "Best of Show" awards for outstanding business plan presentations at the MN Venture Capital Conference held May 8 and 9 in Minneapolis. A group of 12 judges rated 22 presenters on their ability to communicate a clear and compelling business opportunity to investors and attendees. The awards were sponsored by Netsuds.com and Medicalsuds, the conference coordinator, and Spoken Impact, which provided presentation training and consulting to the presenters. Winners in the Medical Category for "Best of Show" were: GOLD - David Land, CEO, Medisyn Technologies. This biotech startup aims to commercialize breakthrough technology that can speed up the drug development lifecycle. Medisyn provides value-added drug discovery services and drug licensing candidates. Pharmaceutical companies can save up to 7 years and $250 Million in traditional research and development costs. In one year, Medisyn's research has produced patent-pending compounds for breast, renal, prostate and lung-cancer treatments. (www.medisyntech.com) SILVER - Kevin Sundquist, CEO, MR Instruments. This revenue generating company is commercializing the next generation imaging coils in the $3B MRI market with 5 patents and trade secrets from world-class scientists. Their priority technology can improve the image quality and lower the cost of every new MRI system and they are first to market in the new, higher field strength magnets that are leading MRI research. (www.mrinstruments.net) BRONZE - Thomas E. Brust, CEO, Micronet Medical. This medical device company has launched the world's first micro-lead technology to address a large unmet need in neurostimulation for chronic pain management. With its superior maneuverability and precise placement, MicroNet's technology increases surgical success rates and has found strong acceptance among key opinion leaders. (www.micronetmedical.com) "Best of Show" winner in the Communications/Internet category: GOLD - Roald Marth, CEO, WhereToLive. The company's web-based software platforms enables real estate brokers and agents to engage in real-time real estate through a suite of tools that leverages the Internet for listing distribution, lead generation, online marketing and contact management. The WhereToLive.com Industry Portal aggregates the broker and agent listings while also providing consumers with a highly intuitive web interface. (www.wheretolive.com) Matt Noah, CEO of NetSuds.com, stated, "Investors from Minnesota, Iowa, Wisconsin, Illinois, North Dakota, California, Arizona, New York and Massachusetts representing over $15 billion dollars in venture capital came to the Conference to look for quality investments. Twenty-two companies gave 15-minute presentations and we all witnessed the follow-up conversations, the private lunches and impromptu meetings in the hallways. Venture capitalists are active and investing in Minnesota." Spoken Impact, Inc. is a public speaking training and consulting firm that helps business executives create and deliver more impactful speeches and presentations. The company can be reached at www.SpokenImpact.com. Netsuds.com, Inc. is a business development and networking organization serving the telecom, datacom, IT and Internet professional in Minnesota. The company produces events which create business opportunities for attendees. NetSuds.com has also extended its mission to serve the medtech, biotech and life sciences professional in Minnesota with its new organization MedicalSuds. More information is available at www.netsuds.com, and www.medicalsuds.com . Questions: Contact Joan Moser at 612-377-3686 About Medisyn Technologies Medisyn Technologies is a unique drug design and discovery company that uses proprietary technology to make drug discovery faster, more predictable and less expensive. Based on molecular topology, Medisyn’s Forward Engineering™ platform enables the discovery and design of novel, diverse and unexpected compounds that meet exact parameters for a specific therapeutic use. By compressing design and discovery time from years to weeks and optimizing lead candidates, Medisyn’s novel approach enables drug discovery customers to reduce risk, improve probability of success and control costs associated with the traditional lead discovery process. The company is initially focused on treating cancer and is currently completing pre-clinical validation of MT103, a promising lead candidate for non-small cell lung cancer. It has an additional 26 anti-cancer compounds in varying stages of development. Medisyn Technologies is headquartered in Minneapolis, MN. For more information about Medisyn Technologies, visit the company’s website at: www.medisyntech.com or call 952.475.8084. Contact: Pam Pettinella LATITUDE 952.404.1853 pam@latitude-c.com Close Window